Our data suggest that in precancerous states and to prevent tumour relapse, EGFR activation—such as through EGF treatment—might provide a competitive advantage to wild-type cells in the presence of neighbours expressing the constitutively active form of a Ras oncogene. Here, EGF is linked to neoplasm.